# LYMPHOMA UK

## Details

- **Country:** England & Wales
- **Charity number:** 1190725
- **Other names:** Lymphoma Research UK, THE KAREN INGRAM FOUNDATION, LYMPHOMA UK
- **Status:** Registered
- **Legal form:** CIO
- **Registered:** Aug. 5, 2020
- **Register:** https://register-of-charities.charitycommission.gov.uk/en/charity-search/?p_p_id=uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_regId=1190725


## Contact

- **Address:** 41 Keyhaven Drive, HAVANT, Hampshire
- **Postcode:** PO9 4BY
- **Phone:** 07480245314
- **Email:** info@lymphoma-uk.org
- **Website:** www.lymphoma-uk.org



## Activities

**Objects:** THE RELIEF OF SICKNESS AND THE PRESERVATION OF HEALTH OF PEOPLE SUFFERING FROM BLOOD CANCER DISEASES BY THE PROVISION OF FINANCIAL ASSISTANCE FOR RESEARCH INTO THE CAUSES OF, AND POSSIBLE CURERS FOR SUCH CANCERS.

**Activities:** LYMPHOMA UK aims to improve the lives of those affected by lymphoma blood cancer by providing grants to medical researchers who undertake clinical cancer trials to see which treatments are most effective at treating the disease.




## Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** The General Public/mankind



## Areas of operation

- Throughout England And Wales



## Finances

| Period end | Income | Expenditure | Assets | Employees |
|---|---|---|---|---|
| April 5, 2025 | £9592 | £22310 | — | — |
| April 5, 2024 | £25077 | £9511 | — | — |
| April 5, 2023 | £8807 | £9158 | — | — |
| April 5, 2022 | £4734 | £4349 | — | — |
| April 5, 2021 | £12476 | £5970 | — | — |



## Trustees

- **Thomas Michael Ingram** (Chair) — appointed Dec. 9, 2024
- Blake Sim-Henry — appointed Nov. 23, 2024
- Rob Tyler — appointed Feb. 1, 2025